April 12, 2021
Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer BookmarkGeorge Lundberg, MD
The ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.
March 16, 2020
Emma Shtivelman, PhD
In 2019 and early 2020, the U.S. Food and Drug Administration (FDA) approved a number of new drugs for bladder cancer of all stages, and more treatments are on the horizon. Here’s a snapshot of what’s happening right now in bladder cancer treatment: Non-muscle invasive bladder cancer treatments (NMIBC) In patients with NMIBC, tumors are confined to the inner cell layer of the bladder… Read more »